Accelerating Cell Therapy Development
ImmunoMind uses AI and multi-omics to predict preclinical and clinical efficacy of cell therapies (CAR-T, TCR-T, Treg, gdT) early, helping drug developers focus on therapies that work.
Moonshot startup from UC Berkeley SkyDeck
We improve the design of T-cell therapies today — to make them more efficient and safer for patients tomorrow
From the team behind Immunarch – the gold standard for T-cell and B-cell data analysis, trusted by:
and the global community of 60,000 medical scientists and researchers worldwide
Pfizer · Novartis · UCSF · Stanford · MIT · MD Anderson Cancer Center ·
The Johns Hopkins University School of Medicine
Platform.
  • x15-25 more cell behavior factors
    affecting efficacy and related to exhaustion and persistence
  • Prioritize efficient CAR/TCR-T leads x10-15 faster from in vitro and in vivo single-cell sequencing data
  • Leverage single-cell and bulk multi-omics technologies for T-cell therapy development
Applications.
Compare essential CAR-T cell population characteristics and choose the most prominent drug candidates.
Early assessment of CAR-T cell population essential characteristics helps improve the probability of success in later drug development stages. ImmunoMind's platform automatically evaluates CAR-T cells' activation, proliferation, cytotoxicity, senescence, and exhaustion. The platform simultaneously compares the characteristics of several CAR-T products and helps companies choose the best candidate.
Request Details
Apply novel strategies to improve the CAR-T product's efficacy by exhaustion estimation.
T cell exhaustion is a dysfunctional state of T-cells arising from excessive antigen stimulation. It is considered to be one of the critical factors at all stages of CAR-T development and manufacturing. ImmunoMind's technologies precisely evaluate CAR-T cell exhaustion and help in developing effective therapies.
Request Details
Address the extensive heterogeneity of CAR-T drugs to reduce toxicity.
Heterogeneity subpopulations and CD4+/CD8+ ratio are vital attributes of CAR-T product that should be analyzed for the development of effective drugs. By using single-cell technologies, it is now possible to dive into the internal context of CAR-T products, while delineating cell subtypes and cell diversity.
Request Details
Improve the CAR-T manufacturing process using cell differentiation insights.
Efficacy is diminished due to the predominance of more differentiated cells in the final CAR-T product. Identification of various differentiated subpopulations results in the ability to optimize the CAR-T manufacturing process. The actionable insights provided by ImmunoMind assist when selecting the most effective composition of a CAR-T product and allow modification of the manufacturing process.
Request Details
Why partner with us?
Biotech Startups – De-risk
De-risk T-cell therapy on the crucial discovery steps by focusing on the most persistent cell therapy candidates.
Cell Therapy Biopharma – Save 6+ months
Focus on cell therapy candidates that work and build internal multi-omics infrastructure to streamline the prioritization of cell therapy candidates.
Research Groups – Discover
Study immune cell biology and discover new T-cell therapies with the AI and bioinformatics capabilities of our AI platform.